Zhang Yan, Li Xing, Zhang Jun, Mao Lin, Wen Zou, Cao Mingliang, Mu Xuefeng
Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
PPAR Res. 2023 May 31;2023:4962460. doi: 10.1155/2023/4962460. eCollection 2023.
A ligand-activated transcription factor, peroxisome proliferator-activated receptor (PPAR) regulates fatty acid uptake and transport. In several studies, upregulation of PPAR expression/activity by cancer cells has been associated with cancer progression. Worldwide, cancer of the cervix ranks fourth among women's cancers. Angiogenesis inhibitors have improved treatment for recurrent and advanced cervical cancer since their introduction 5 years ago. In spite of that, the median overall survival rate for advanced cervical cancer is 16.8 months, indicating that treatment effectiveness is still lacking. Thus, it is imperative that new therapeutic methods be developed. In this work, we first downloaded the PPAR signaling pathway-related genes from the previous study. In addition, the single-sample gene set enrichment analysis (ssGSEA) algorithm was applied to calculate the PPAR score of patients with cervical cancer. Furthermore, cervical cancer patients with different PPAR scores show different sensitivity to immune checkpoint therapy. In order to screen the genes to serve as the best biomarker for cervical cancer patients, we then construct the PPAR-based prognostic prediction model. The results revealed that PCK1, MT1A, AL096855.1, AC096711.2, FAR2P2, and AC099568.2 not only play a key role in the PPAR signaling pathway but also show good predictive value in cervical cancer patients. The gene set variation analysis (GSVA) enrichment analysis also proved that the PPAR signaling pathway is one of the most enriched pathways in the prognostic prediction model. Finally, further analysis revealed that AC099568.2 may be the most promising biomarker for the diagnosis, treatment, and prognosis in cervical cancer patients. Both the survival analysis and Receiver Operating Characteristic curve demonstrated that AC099568.2 plays a key role in cervical cancer patients. However, to our knowledge, this is the first time a study focused on the role of AC099568.2 in cervical cancer patients. Our work successfully revealed a new biomarker for cervical cancer patients, which also provides a new direction for future research.
配体激活转录因子过氧化物酶体增殖物激活受体（PPAR）可调节脂肪酸摄取和转运。在多项研究中，癌细胞中PPAR表达/活性的上调与癌症进展相关。在全球范围内，宫颈癌在女性癌症中排名第四。自5年前引入以来，血管生成抑制剂改善了复发性和晚期宫颈癌的治疗。尽管如此，晚期宫颈癌的中位总生存率为16.8个月，这表明治疗效果仍不足。因此，开发新的治疗方法势在必行。在这项工作中，我们首先从先前的研究中下载了PPAR信号通路相关基因。此外，应用单样本基因集富集分析（ssGSEA）算法计算宫颈癌患者的PPAR评分。此外，不同PPAR评分的宫颈癌患者对免疫检查点治疗表现出不同的敏感性。为了筛选出可作为宫颈癌患者最佳生物标志物的基因，我们随后构建了基于PPAR的预后预测模型。结果显示，PCK1、MT1A、AL096855.1、AC096711.2、FAR2P2和AC099568.2不仅在PPAR信号通路中起关键作用，而且在宫颈癌患者中也显示出良好的预测价值。基因集变异分析（GSVA）富集分析也证明，PPAR信号通路是预后预测模型中最富集的通路之一。最后，进一步分析表明，AC099568.2可能是宫颈癌患者诊断、治疗和预后最有前景的生物标志物。生存分析和受试者工作特征曲线均表明，AC099568.2在宫颈癌患者中起关键作用。然而，据我们所知，这是首次有研究关注AC099568.2在宫颈癌患者中的作用。我们的工作成功揭示了一种新的宫颈癌患者生物标志物，也为未来研究提供了新方向。
